PATENT AND TECHNOLOGY SUBLICENSE AGREEMENT

This Patent and Technology Sublicense Agreement (this “Agreement”) is entered into as of January 5, 2020 (the “Effective Date”), by and between among Bakhu Holdings, Corp., a Nevada corporation (“Sublicensor”) and CBD Biotech, Inc., a California corporation (“Sublicensee”). Sublicensor and Sublicensee are sometimes hereinafter individually referred to as a “Party” and collectively as the “Parties.”

RECITALS

A.                  Sublicensor and Cell Science Holding Ltd., a corporation organized under the laws of the Republic of Cyprus (“Licensor”) are parties to that certain Amended and Restated Patent and Technology License Agreement dated December 31, 2019 (the “Master License Agreement”), a copy of which is attached hereto as Exhibit A, pursuant to which Licensor has licensed to Sublicensor, on a fully paid-up, royalty-free basis, all of the Licensed Science (as defined in the Master License Agreement) to make or have made the Licensed Product (as defined in the Master License Agreement) and to use, sell, lease, offer to sell, import or otherwise dispose of the Licensed Product in all countries and all territories worldwide, (the “Master Agreement Territory”) and subject to the terms and conditions of the Master License Agreement.

B.                  Licensor is the sole owner of all right, title and interest in and to the Licensed Science (which includes the inventions and subject matter disclosed in the Patents) and Sublicensor holds the exclusive license to the Licensed Science;

C.                  The Master License Agreement grants Sublicensor the right, from time to time, to sublicense to any third party or parties, on a non-exclusive basis, all or a portion of its rights under the Master License Agreement.

D.                  Sublicensor desires to sublicense the Licensed Science to Sublicensee as its relates to the production, methods, and products of CBD and its derivatives, and Sublicensee desires to acquire and receive a license of the Licensed Science from Sublicensor for the purpose of making the Licensed Products, all on the terms and conditions contained herein.

AGREEMENTS

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

ARTICLE 1.

DEFINITIONS

Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms below:

1.1               “Affiliate” means, with respect to any Person, any other Person controlling, controlled by or under common control with such first Person. For purposes of this definition and the Agreement, the term “control” (and correlative terms) means (a) the ownership of 50% or more of the equity interest in a Person, or (b) the power, whether by contract, equity ownership or otherwise, to direct or cause the direction of the policies or management of a Person.

1.4               “Assignment” has the meaning set forth in Section 10.5.

1.5               “Bankruptcy” means the filing by a Person of a petition commencing a voluntary case under the Bankruptcy Code; a general assignment by a Person for the benefit of creditors; an admission in writing by a Person of its inability to pay debts as they become due; the seeking or acquiescence by a Person in the appointment of any trustee, receiver, or liquidator for the Person or for any part of the Person’s property; or the commencement against a Person of an involuntary case under the Bankruptcy Code, or a proceeding under any receivership, composition, readjustment, liquidation, insolvency, dissolution or similar law or statute, if not dismissed or vacated within 60 days.

1.6               “Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder and guidance issued in conjunction therewith.

1.7               “Distributor” shall mean any entity or other person, other than an Affiliate of Licensee, which purchases finished Licensed Products from Licensee or an Affiliate of Licensee solely for the purpose of resale to an End User

1.8               “Effective Date” has the meaning set forth in the opening paragraph.

1.9               “End User” shall mean the entity or person that purchases a Licensed Product for intended use.

1.10           “Field” means the (a) production and manufacturing of CBD, CBD byproducts and CBD derivatives, from non-psychoactive, low-THC cannabis sativa plant strains and cannabinoids (collectively, “Cannabis”), for Sale and use at retail or wholesale where permitted, including, without limitation, CBD food additives, CBD edibles, and CBD hemp variations of the foregoing; (b) CBD-related research, teaching and education for both medical and other purposes; and (c) all medical uses and applications of CDB. The Field is exclusive to production, methods, and products of CBD and its derivatives, and excludes and prohibits any THC related products having a measureable tetrahydrocannabinol concentration potency above 3.0% on a dry weight basis, production methods, techniques, or Know How.

1.11           “Governmental Authority” means a federal, state, or local governmental authority; a state, province, commonwealth, territory or district thereof; a county or parish; a city, town, township, village or other municipality; a district, ward or other subdivision of any of the foregoing; any executive, legislative or other governing body of any of the foregoing; any agency, authority, board, department, system, service, office, commission, committee, council or other administrative body of any of the foregoing; any court or other judicial body; and any officer, official or other representative of any of the foregoing.

1.12           “Improvements” means those modifications, revisions, derivations, updates, enhancements and improvements of the Licensed Science that are conceived, discovered, created, developed or acquired by or on behalf of Licensor, which Improvements will automatically and without any further action on the part of Licensor or Sublicensee, become part of the Licensed Science (and part of the Patent and Technology License).

1.13           “IRS” means the United States Internal Revenue Service, and any successor thereto.

1.14           “Know-How” means technical information, ideas, concepts, confidential information, trade secrets, know-how, discoveries, inventions, processes, methods, formulas, source and object codes, data, programs, other works of authorship, improvements, developments, designs and techniques related to the field other than as embodied in the Patents, that are owned or controlled by Licensor during the Term and that are necessary or desirable to use the Patents for the purpose of the license granted in Section 2 hereof.

1.15           “License Fee” has the meaning set forth in Section 2.4.

1.16           “Licensed Products” means any CBD products or methods related to the Field, whether owned by Licensor or Sublicensor or licensed by Licensor or Sublicensor now or hereafter, that are (i) covered by any Valid Claim(s) contained in any of the Patents, and/or (ii) based on the products, processes or methods developed using the Licensed Science.

1.17           “Licensed Science” means and includes anything and everything encompassed by the Licensed Process, the Licensed Product in the Field, and the Licensed Service, as well as any Improvements developed or acquired after the Effective Date which is related to the subject matter in the Patents, whether or not such Improvements becomes the subject of a patent application during the Term.

1.18           “Licensed Service” means performance of a service using a Licensed Product, or the practice of a Licensed Process. For clarity, non-profit research and development of Licensed Products by Sublicensor, its Affiliates, or Sublicensees do not constitute a Licensed Service.

1.19           “Loss” means losses (but expressly excluding any lost or disallowed tax credits), liabilities, demands, assessments, cleanup, removal, remediation and restoration obligations, judgments, awards, damages, natural resource damages, contribution, cost-recovery and compensation obligations, fines, fees, penalties, costs and expenses (including litigation and arbitration costs and attorneys’ and experts’ fees and expenses).

1.20           “Master License Agreement” has the meaning set forth in Recital A.

1.21           “Net Annual Sales” shall mean the total of the total gross invoiced price paid to licensee of all Licensed Products sold or otherwise transferred by Licensee or any Affiliate of Licensee to an End User or Distributor in the Territory during a specific calendar year.

1.24           “Patents” means: (i) United States Patent Application No. 16/290,708, (ii) United Kingdom Patent Application No. 1717554.8, (iii) Patent Cooperation Treaty Application No. 2018/077149 and (iv) any and all continuations, continuations-in-part, and divisionals, and all patents issuing which are based on such applications, and all reissues, reexaminations, or extensions thereof, as well as any foreign counterparts, continuations, continuations-in-part or divisions thereof and patents and patent applications on any improvements, advancements, modifications, revisions or developments to the subject matter claimed in the aforesaid patents that are developed by or for Licensor, together with any other patents (U.S. or foreign and even if not listed herein) that share a common claim of priority with said patents or that, as mutually agreed upon in good faith by the Parties, cover inventions substantially similar to said patents.

1.25           “Person” means an individual, corporation, partnership, limited liability company, association, trust, unincorporated organization or other entity.

1.26           “Licensed Science Sublicense” has the meaning set forth in Section 2.1

1.27           “Term” means the period commencing on the Effective Date and ending on the date provided in Section 4.1 herein.

1.28           “Territory” means any and all countries in the continent of North American, defined as the United States of America, Canada, Mexico, all countries in the Caribbean Sea and all countries north of the Panama/Columbia boarder (including the entire nation of Panama).

1.29           “Trade Secrets” has the meaning set forth in Section 8.4.

1.30           “Valid Claim(s)” means any claim contained in an issued and unexpired patent included within the Patents that has not been held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction, or unappealable or unappealed within the time allowed for appeal, and that has not been admitted to be invalid or unenforceable through reissue or disclaimer.

ARTICLE 2.

SUBLICENSE GRANT

2.1               Grant. Sublicensor hereby grants to Sublicensee, and Sublicensee hereby accepts, a transferable (but only to the extent provided in Section 2.3 below), non-exclusive right and license under the Licensed Science to make or have made the Licensed Products and to use the Licenses Science Patents, Know-How, and Licensed Products in connection with the Field, including the distribution, sale, and marketing thereof, in the Territory (the “Licensed Science Sublicense”).

2.2               Scope of License. The Licensed Science Sublicense granted hereby is for the purpose of engaging in the business of producing and selling Licensed Products, and to do any and all things necessary or incidental thereto subject to the terms and conditions of the Licensed Science Sublicense.

2.3               Right to Sublicense. Subject to and conditioned upon the prior written approval of Sublicensor, the Sublicensee may, from time to time, sublicense to any other third party all its rights granted under this Sublicense.

2.4               License Fee. In consideration of, and as full payment for, the rights and license granted to Sublicensee under this Agreement, Sublicensee will issue to Sublicensor, within seven (7) days of the execution of this Agreement, nine million (9,000,000) shares of common stock, no par value per share (the “Common Stock”) of the Sublicensee.

ARTICLE 3.

TECHNICAL ASSISTANCE AND IMPROVEMENTS

3.1               Sublicensor shall promptly and fully advise Sublicensee in writing of any Improvements, it being understood that any Improvements conceived, discovered, created, developed or acquired by Sublicensor or Licensor during the Term will be the property of Sublicensor or Licensor, as applicable, and will be included within the Licensed Science and thereby made a part of the Licensed Science Sublicense granted to Sublicensee for the remaining duration of this Agreement. The expenses of filing and prosecuting any patent application relating to such Improvements will be borne by Licensor.

3.2               All inventions, improvements, or Know-How (based on the Licensed Science) that are conceived, discovered, created, developed or acquired by or on behalf of Sublicensee or by any of the Parties jointly are to be owned by Licensor, and all right, title and interest in and to such inventions, improvements, or Know-How are hereby assigned by Sublicensee and Sublicensor, as appropriate, to Licensor. Sublicensee and Sublicensor shall promptly and fully advise Licensor in writing of such inventions, improvements, or Know-How that are material and of which it becomes aware. All right, title, and interest in any inventions, improvements, or Know-How (with respect to the subject matter of the Licensed Science) that are conceived, discovered, created, developed or acquired (a) by or on behalf of Sublicensee or (b) by any of the Parties jointly will be sublicensed and are hereby sublicensed to Sublicensee as part of the Licensed Science Sublicense. The expenses of filing and prosecuting any patent application relating to any such inventions, improvements, or Know How will be borne by Licensor; provided, however that Sublicensee and Sublicensor, as appropriate, shall reasonably assist Licensor, at Licensor’s sole expense, in obtaining Licensor’s full ownership rights, including patent rights, in and to the subject inventions, improvements, or Know-How.

ARTICLE 4.

TERM AND TERMINATION

4.1               Term. Unless earlier terminated as provided herein, the term of this Agreement is from the Effective Date until the expiration of all patents issued under Patent Rights (if any) and the cancellation, withdrawal, or express abandonment of all patent applications under Patents Rights (if any). Notwithstanding the foregoing, the license granted to Licensee under this Agreement for Licensed Science that is not subject to an expiration of a Patent Right shall continue in perpetuity.

4.2               Other Termination. Any Party may terminate this Agreement prior to the end of the Term upon providing written notice to the other Party if the other Party commits a material default or breach of any representation, warranty, covenant or agreement contained herein and, if remediable, the defaulting or breaching party fails to remedy any such default or breach within 30 days after receiving written notice describing in reasonable detail the material default or breach from the non-defaulting or non-breaching Party. Notwithstanding the preceding sentence in the event that an alleged default or breach is caused by or a result of the actions of a third party, upon the defaulting or breaching party demonstrating that the alleged default or breach is curable but the time to cure such default of breach exceeds the 30 day cure period, the cure period will be extended to such reasonable time cure in light of the applicable circumstances. By way of example, if the Sublicensee received a cease and desist letter from a state or federal government agency for review of operations, the notice, response and review guidelines for such an inquiry will normally exceed ninety days, and in such an event the applicable cure period would be extended accordingly.

4.3               Effect of Termination of this Agreement or the Patent and Licensed Science License under Certain Circumstances. The rights of Sublicensee set forth in Article 2., will survive any termination of this Agreement or the Patent and Technology License or the dissolution of the Sublicensor; provided any such termination of this Agreement does not occur as a result of a breach of this Agreement by Sublicensee (each of the foregoing, a “No-Fault Termination Event”). Licensor hereby grants to Sublicensee all of the rights and licenses granted to Sublicensee by Sublicensor hereunder (including the Licensed Science Sublicense). Sublicensee shall not exercise such rights and licenses unless and until a No-Fault Termination Event has occurred and the Licensed Science Sublicense granted hereunder has been terminated. Notwithstanding anything to the contrary in this Agreement or the License Agreement (including Section 5 thereof), upon the occurrence of a No-Fault Termination Event resulting in the termination of the License Agreement, the termination of this Agreement or the dissolution of the Sublicensor (as applicable), Sublicensee may exercise the rights and licenses set forth in this Section 4.3 and Licensor will assume all obligations of Sublicensor in this Agreement, both without any further action by any of the Parties.

4.4               Effect of Bankruptcy of Sublicensor or Licensor. Sublicensor and Licensor acknowledge and agree that the Intellectual Property rights licensed to Sublicensee hereunder constitute “intellectual property” as such term is defined in the Bankruptcy Code and that Sublicensee is entitled to all of the rights of a licensee of intellectual property under Section 365(n) of the Bankruptcy Code with respect to all of such licensed rights, which rights under the Bankruptcy Code include, without limitation, the right, upon the rejection of this Agreement or the License Agreement in any case filed under the Bankruptcy Code with respect to Sublicensor and/or Licensor, to treat this Agreement or the License Agreement as terminated or to retain Sublicensee’s rights under this Agreement or the License Agreement, and under any agreements supplemental to this Agreement or the License Agreement, with respect to such rights (including any embodiment of the rights to the extent protected by applicable non-bankruptcy law), as such rights existed immediately before the Sublicensor’s and/or Licensor’s bankruptcy case commenced. If Sublicensee elects to retain such licensed rights under this Agreement or the License Agreement, then Sublicensee may exercise such licensed rights in accordance with the terms and conditions of this Agreement or the License Agreement. Nothing contained herein shall limit any other rights provided to Sublicensee under the Bankruptcy Code, including Section 365(n) thereof.

ARTICLE 5.

REPRESENTATIONS AND WARRANTIES

Each Party hereby represents and warrants to the other Party as of the Effective Date (except where a representation and warranty speaks as of another date) as follows: 

5.1               By Sublicensee. Sublicensee represents and warrants to Licensor and Sublicensor that:

(a)                it has the full right, power and authority to enter into this Agreement and perform its obligations hereunder;

(b)                it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and is qualified to conduct its business in those jurisdictions necessary to perform this Agreement;

(c)                this Agreement constitutes the legal, valid and binding obligation of Licensee enforceable in accordance with its terms, subject, however, to the effects of bankruptcy, insolvency, reorganization, moratorium and similar laws from time to time in effect, as well as to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

(d)                all necessary limited liability company or corporate action has been taken to authorize, and all necessary authorizations, notices and consents of any third party which are required to authorize, Licensee to execute and deliver, and to perform the transactions contemplated by, this Agreement have been obtained and remain in full force and effect; and,

(e)                the execution, delivery and performance of this Agreement are within its powers, have been duly authorized by all necessary action and do not violate any of the terms or conditions in its limited liability company agreement or other governing documents or any contract to which it is a party or by which any of its properties is bound or any law, rule, regulation, order, writ, judgment, decree or other legal or regulatory determination of any governmental entity applicable to it.

5.2               By Licensor. Licensor represents and warrants to Sublicensee and Sublicensor that:

(a)                it has the full right, power and authority to enter into this Agreement and perform its obligations hereunder;

(b)                it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and is qualified to conduct its business in those jurisdictions necessary to perform this Agreement;

(c)                this Agreement constitutes the legal, valid and binding obligation of Licensor enforceable in accordance with its terms, subject, however, to the effects of bankruptcy, insolvency, reorganization, moratorium and similar laws from time to time in effect, as well as to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

(d)                the Patent and Technology License constitutes the legal, valid and binding obligation of Licensor enforceable in accordance with its terms, subject, however, to the effects of bankruptcy, insolvency, reorganization, moratorium and similar laws from time to time in effect, as well as to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

(e)                all necessary limited liability company or corporate action has been taken to authorize, and all necessary authorizations, notices and consents of any third party which are required to authorize, Licensor to execute and deliver, and to perform the transactions contemplated by, this Agreement have been obtained and remain in full force and effect;

(f)                 the execution, delivery and performance of this Agreement are within its powers, have been duly authorized by all necessary action and do not violate any of the terms or conditions in its limited liability company agreement or other governing documents or any contract to which it is a party or by which any of its properties is bound or any law, rule, regulation, order, writ, judgment, decree or other legal or regulatory determination of any governmental entity applicable to it;

(g)                it owns all right, title and interest in and to the Patents, Licensed Science, and Know-How;

(h)                it has the full right and authority to grant the Licensed Science Sublicense to Sublicensee;

(i)                 there are no outstanding agreements, assignments or encumbrances inconsistent with the provisions of this Agreement;

(j)                 none of the Patents have been invalidated either wholly or partly by a tribunal or court of law within the United States or abroad or by the United States Patent and Trademark Office or any of its foreign equivalents and to the knowledge of Licensor there are no proceedings attempting to do so;

(k)                the Patents are valid and enforceable;

(l)                 neither the Patents nor the, Licensed Science or Know-How infringe or misappropriate any patent, trade secret or other intellectual property right of any third party;

(m)              Licensor has not received any notice alleging its noncompliance with any Applicable Law with respect to the Patents, Know-How, Licensed Science, or Licensed Products;

(n)                Licensor has not threatened or initiated any claim, suit or proceeding against any third party alleging that such third party has infringed or misappropriated any rights under the Patents, Licensed Science, and/or Know-How and, to the knowledge of Licensor, no third party is infringing or misappropriating any such rights; and

(o)                the Patents, Licensed Science, and Know-How, along with know-how generally available in the Field, are all the intellectual property rights necessary for the manufacture of the Licensed Products.

5.3               By Sublicensor. Sublicensor represents and warrants to Sublicensee and Licensor that:

(a)                it has the full right, power and authority to enter into this Agreement and perform its obligations hereunder;

(b)                it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its formation and is qualified to conduct its business in those jurisdictions necessary to perform this Agreement;

(c)                this Agreement constitutes the legal, valid and binding obligation of Sublicensor enforceable in accordance with its terms, subject, however, to the effects of bankruptcy, insolvency, reorganization, moratorium and similar laws from time to time in effect, as well as to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

(d)                the Patent and Technology License constitutes the legal, valid and binding obligation of Sublicensor enforceable in accordance with its terms, subject, however, to the effects of bankruptcy, insolvency, reorganization, moratorium and similar laws from time to time in effect, as well as to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law);

(e)                all necessary limited liability company or corporate action has been taken to authorize, and all necessary authorizations, notices and consents of any third party which are required to authorize, Sublicensor to execute and deliver, and to perform the transactions contemplated by, this Agreement have been obtained and remain in full force and effect;

(f)                 the execution, delivery and performance of this Agreement are within its powers, have been duly authorized by all necessary action and do not violate any of the terms or conditions in its limited liability company agreement or other governing documents or any contract to which it is a party or by which any of its properties is bound or any law, rule, regulation, order, writ, judgment, decree or other legal or regulatory determination of any governmental entity applicable to it;

(g)                it has the full right and authority to grant the Licensed Science Sublicense to Sublicensee;

(h)                there are no outstanding agreements, assignments or encumbrances inconsistent with the provisions of this Agreement;

(i)                 Sublicensor has not received any notice alleging its noncompliance with any Applicable Law with respect to its license of the Patents, Know-How, Licensed Science, or Licensed Products;

(j)                 Sublicensor has not threatened or initiated any claim, suit or proceeding against any third party alleging that such third party has infringed or misappropriated any rights under the Patents, Licensed Science and/or Know-How and, to the knowledge of Sublicensor, no third party is infringing or misappropriating any such rights.

ARTICLE 6.

LIMITATION OF LIABILITY

6.1               With the exception of the parties’ obligations under Article 8 or any willful misconduct or gross negligence by a party, in no event shall any party be liable to any other party or any third party for any special, consequential, indirect or incidental damages, however caused, on any theory of liability whether or not a party has been advised of the possibility of such damages, arising in any way out of this agreement.

ARTICLE 7.

MAINTENANCE OF PATENT RIGHTS

7.1               Pursuant to the Master License Agreement, Licensor shall be solely responsible for and shall pay all fees, costs or expenses of any nature required to prosecute, defend or maintain the Patents and will use reasonable commercial efforts to maintain and enhance the scope of the Valid Claim(s). Pursuant to the Master License Agreement if any claim contained in an issued and unexpired patent included within the Patents is held unenforceable, unpatentable or invalid by a decision of a tribunal, court, or other governmental agency of competent jurisdiction, then Licensor will, at its sole expense, use reasonable commercial efforts to create, develop and/or secure functionally equivalent workarounds and, where commercially appropriate, prosecute patent applications and or patents for the same, which patent applications and/or patents will automatically be included within the Patents.

ARTICLE 8.

PROTECTION OF LICENSED SCIENCE

8.1               Pursuant to the Master License Agreement, it shall be the obligation of Licensor, at its sole cost and expense, in Licensor’s name, to protect and enforce the Patents and to prosecute or settle any third-party infringement of the Patents pursuant to the terms of the Master License Agreement. If pursuant to the Master License Agreement the Licensor determines not to diligently enforce the Patents, (in which case Licensor shall promptly notify Sublicensor in writing of the same, or if it comes to the attention of Sublicensee that Licensor is not diligently enforcing the Patents then, subject to the rights of Licensor and other licensees of the Patents (i) Sublicensee will have the right to enforce the Patents at Sublicensee’s sole expense, (ii) if requested by Sublicensee, Licensor and Sublicensor will cooperate in Sublicensee’s prosecution or defense of any dispute resolution, litigation or settlement activities hereunder, provided that Sublicensee will reimburse Licensor for all reasonable costs incurred by Licensor as a result of such cooperation, and (iii) any recoveries will be awarded to Sublicensor and Sublicensee (and any other participating licensees or sublicensees) in an amount that is proportional to their costs in so enforcing the Patents.

8.2               Indemnity by Sublicensee. Sublicensee shall defend, indemnify and hold harmless Licensor, Sublicensor and their respective Affiliates and their respective members, managers, stockholders, officers, employees, agents, representatives and attorneys against any Loss arising from or in connection with any breach by Sublicensee of the representations and warranties in Section 5.1.

8.3               Indemnity by Sublicensor. Sublicensor shall defend, indemnify and hold harmless Licensor and Sublicensee and their respective Affiliates and their respective members, managers, stockholders, officers, employees, agents, representatives and attorneys against any Loss arising from or in connection with any breach by Sublicensor of the representations and warranties in Section 5.3.

8.4               Protection and Enforcement of Licensed Science, Know-How and Trade Secrets. Sublicensor and Sublicensee will at all times during the Term use commercially reasonable efforts to preserve and protect the confidentiality of all portions of the Licensed Science, Know-How and any other information provided it such Persons that constitute “trade secrets” as that term is defined in the Uniform Trade Secret Act (the “Trade Secrets”). Furthermore, if it comes to the attention of Licensor that any Trade Secret has been misappropriated by any third party, then Licensor will use all reasonable efforts, including legal actions, to preserve and protect the confidentiality of the Trade Secret and to prevent such third party from any and all uses of the Trade Secret, so long as doing so is commercially reasonable to benefit either Licensor or Sublicensee.

8.5               Sublicensee’s Obligation to Notify Licensor of Possible Infringements or Misappropriation. Sublicensee shall notify Licensor, in writing, if it comes to the attention of Sublicensee that any of the Patents is being infringed or any Trade Secret has been or is in danger of being misappropriated by any third party, including in such notice a summary of relevant facts underlying Sublicensee’s belief as to such infringement or misappropriation.

ARTICLE 9.

CONFIDENTIALITY

9.1               Each Party shall maintain the terms of this Agreement in confidence and shall not disclose any information concerning the terms, performance or administration of this Agreement to any other Person; provided that a Party may disclose such information: (a) to any of such Party’s Affiliates, (b) to any prospective member of such Party’s Affiliates, (c) to any actual or prospective purchaser of all or a portion of such Party and (d) to any Person providing or evaluating a proposal to provide financing to the recipient Party or any direct or indirect owner of such Party; provided in each case that the recipient Party shall provide to each Person to which disclosure is made a copy of this Article 9 and direct such Person to treat such information confidentially, and the recipient Party shall be liable for any breach of the terms of Article 9 by such Persons to which it makes any such disclosure. The foregoing restrictions will not apply (i) to information that is or becomes generally available to the public otherwise than as a result of disclosure by the recipient Party, (ii) to information that is already in, or subsequently comes into, the recipient Party’s possession, provided that the source of such information was not, to the recipient Party’s knowledge, obligated to keep such information confidential and the information was not received solely pursuant to a previous agreement between the Parties , (iii) to information that is required to be disclosed pursuant to Law or stock exchange rules and regulations or is otherwise subject to legal, judicial, regulatory or self-regulatory requests for information or documents, or (iv) subject to Section 9.2 below, to the tax treatment or tax structure of the transaction.

9.2               If any Party is required to disclose any information required by this Article 9., to be maintained as confidential in a judicial, administrative or governmental proceeding, such Party shall give the other Party at least 10 days’ prior written notice (unless less time is permitted by the applicable proceeding) before disclosing any such information in any said proceeding and, in making such disclosure, the Party required to disclose the information shall disclose only that portion thereof required to be disclosed and shall cooperate with the other Party in the other Party’s attempts to seek to preserve the confidentiality thereof, including if such Party seeks to obtain protective orders and/or any intervention.

ARTICLE 10.

GENERAL PROVISIONS

10.1           Notices. All notices and other communications among the Parties shall be in writing and shall be deemed to have been duly given (a) when delivered in person, (b) when delivered by a nationally recognized delivery service or (c) when delivered by e-mail with receipt confirmed, addressed as the Recipient or Discloser, as follows:

Notices to Sublicensor:

Bakhu Holdings, Corp.

One World Trade Center, Suite 130

Long Beach, CA 90831

Attn: Thomas K. Emmitt

E-mail: tkemmitt@yahoo.com

Notices to Sublicensee:

CBD Biotech, Inc.

One World Trade Center, Suite 130

Long Beach, CA 90831

Each Party shall update the other Party in writing with any changes in its contact information.

10.2           Binding Effect; Third Parties. The terms and provisions of this Agreement shall be binding upon and shall inure to the benefit of the Parties and their successors and permitted assigns. Nothing in this Agreement shall be deemed to grant any third-party beneficiary or similar rights to any Person not a signatory to this Agreement.

10.3           Construction. The words “this Agreement,” “herein,” “hereby,” “hereunder,” and “hereof,” and words of similar import, refer to this Agreement as a whole (including all Annexes, Exhibits and Schedules) and not to any particular subdivision unless expressly so limited. The words “this Section,” “this subsection,” and words of similar import, refer only to the Sections or subsections hereof in which such words occur. The word “or” is not exclusive, and the word “including” (in its various forms) means “including without limitation.” Pronouns in masculine, feminine, or neuter genders shall be construed to state and include any other gender and words, terms, and titles (including terms defined herein) in the singular form shall be construed to include the plural and vice versa, unless the context otherwise expressly requires. Unless the context otherwise requires, all defined terms contained herein shall include the singular and plural and the conjunctive and disjunctive forms of such defined terms, and the term “Annex,” “Exhibit” or “Schedule” shall refer to an Annex, Exhibit or Schedule attached to this Agreement.

10.4           Governing Law; Jurisdiction and Venue. This Agreement will be construed and enforced in accordance with laws of the U.S. and the State of California, without regard to any choice of law and/or conflicts of law principles which would otherwise refer to and apply the laws of another jurisdiction. Any legal suit, action, proceeding, or dispute arising out of or related to this Agreement or the other agreements referred to herein, shall be instituted in the federal courts of the United States of America or the Superior Courts of the State of California, in each case located in the County of Los Angeles, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, proceeding, or dispute.

10.5           Waiver of Jury Trial. To the fullest extent permitted by applicable law, the Parties hereto hereby voluntarily and irrevocably waives trial by jury in any Proceeding brought in connection with this Agreement, any of the related agreements and documents, or any of the transactions contemplated hereby or thereby.

10.6           Modification. Any modification of this Agreement will be effective only if it is in writing and signed by duly authorized representatives of both Parties. No modification will be made by e-mail communications.

10.7           Severability. If any provision hereof is held to be invalid, illegal or unenforceable in any jurisdiction, the Parties hereto shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties, and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such other provisions in any other jurisdiction, so long as the essential essence of this Agreement remains enforceable

10.8           Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to confer any benefits, rights or remedies on any entity, other than the Parties and their permitted successors and assigns.

10.9           Entire Agreement. This Agreement constitutes the entire agreement between the Parties regarding the subject matter hereof, and supersedes all prior written or verbal agreements, representations and understandings relative to such matters.

10.10        Integration. This Agreement constitutes the entire agreement of the Parties with respect to the subject matter hereof and supersedes all prior representations, assurances, courses of dealing, agreements, and undertakings, whether written or oral, between the Parties concerning such subject matter.

10.11        Titles and Headings. Titles and headings as used in this Agreement are for convenience and reference only, and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation, construction or meaning of any provision.

10.12        Assignment. No Party shall assign, sublease or otherwise transfer (collectively, an “Assignment”) this Agreement or any of its rights hereunder without the prior written consent of the other Parties, and any purported Assignment made without such prior written consent shall be void. Notwithstanding the foregoing:

(a)        any Party may, without the need for consent from the other Parties, make an Assignment of this Agreement to an Affiliate of such Party provided that such Affiliate assumes all of the obligations of the Party making the Assignment, and in such event the Assigning Party shall be released from its obligations under this Agreement, except for those obligations that arose prior to such Assignment;

(b)        Sublicensee may, without the need for consent from Sublicensor or Licensor, make an Assignment of this Agreement to any Person succeeding to all or substantially all of its assets.

10.13        Amendment; Modification, and Waiver. This Agreement may not be amended or modified except by an instrument in writing signed by each of the Parties. Any failure of Sublicensee, Sublicensor, or Licensor to comply with any obligation, covenant, agreement, or condition contained herein may be waived only if set forth in an instrument in writing signed by the Party to be bound thereby, but such waiver or failure to insist upon strict compliance with such obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any other failure.

10.14        Severability of Provisions. If any term or other provision of this Agreement is invalid, illegal, or incapable of being enforced by any rule of Applicable Law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated herein are not affected in any manner materially adverse to any Party. Upon such determination that any term or other provision is invalid, illegal, or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated herein are consummated as originally contemplated to the fullest extent possible.

10.15        Entire Agreement. This Agreement shall constitute the entire agreement between the Parties hereto relating to the subject matter hereof. This Agreement expressly supersedes all prior agreements between the Parties relating to the subject matter hereof.

10.16        Counterparts. This Agreement may be executed and delivered (including by facsimile transmission) in one or more counterparts, all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered to the other Parties, it being understood that all Parties need not sign the same counterpart.

10.17        Survivability on Termination. The provisions of Article 8, 8 and 10, and any other provision hereof which, by its terms, expressly provides that it survive termination of the Term, shall survive the termination of the Term for any reason. All other rights and obligations of the Parties shall cease upon termination of the Term or other termination of this Agreement.

10.18        Further Assurances. Each Party shall execute and deliver to any other Party such further documents, instruments and assurances as may be reasonably requested by such other Party to fulfill the intent of the Parties hereto.

*** Signature Page Follows ***

IN WITNESS WHEREOF, the Parties hereto have caused their duly authorized representatives to execute this Agreement as of the Effective Date first above written.

EXHIBIT A

Master License Agreement

between

Cell Science Holding Ltd. and Bakhu Holdings Corp.

EFFICACY DEMONSTRATION LABORATORY AGREEMENT

THIS EFFICACY DEMONSTRATION LABORATORY AGREEMENT (this “Agreement”) is entered into this 10th day of June, 2020, to memorialize and document an arrangement, understanding, and agreement by and between BAKHU HOLDINGS, CORP., a Nevada corporation (“Bakhu”), and THE OZ CORPORATION, a California corporation (“OZ”), that commenced on and as of May 1, 2020 (the “Effective Date”), on the following:

Premises

A.                 Bakhu acquired a right and license to conduct certain activities respecting a specified territory for intellectual property and know-how, including patent rights, generally relating to producing and manufacturing cannabis sativa and cannabinoids, all pursuant to, as provided in, and in accordance with that certain Patent and Technology License Agreement dated December 20, 2018, as amended and restated in that certain Amended and Restated Patent and Technology License Agreement dated December 31, 2019, and as further amended or supplemented from time to time hereafter (collectively, the “License”), by and between Cell Science Holding Ltd., a Cypress corporation (“Cell Science”), which appears therein as Licensor, and Bakhu, which appears therein as Licensee. Under the License, substantial financial benefits accrue to Cell Science and its stockholders, including OZ, on successful completion of the Efficacy Demonstration. Capitalized terms used but not defined in this Agreement will have the meanings ascribed them in the License.

B.                  Pursuant to the License, Bakhu is required to complete and pay the costs of an “Efficacy Demonstration” of the propriety science underlying the licensed technology as specified in the License.

C.                  At the time the License was completed, Bakhu did not have the established financial, technical, or management resources to initiate the preparation work for the Efficacy Demonstration. Accordingly, OZ initiated these efforts at its own cost and risk. Accordingly, on March 8, 2019, OZ, Cell Science, and VO Leasing Corp., a California corporation (“VOLC”), entered into that certain Research and Develop Agreement respecting the Efficacy Demonstration (the “R&D Agreement”). VOLC is lessee of a facility located at 15614 Oxnard Avenue, Sherman Oaks, California (the “Facility”) that is suitable for a laboratory to conduct research and development of cannabis cell growing and cell growth technology relating to the Efficacy Demonstration. VOLC has represented that it has all required and applicable licenses, regulatory authorizations, and consents from all governmental authorities required to conduct the proposed activities involving cannabis and cannabis components, products, or derivatives at the Facility.

D.                 The work to be undertaken by or at the direction of OZ under the R&D Agreement is intended to meet the requirements under the License to complete an Efficacy Demonstration, which is necessary to trigger certain events, rights, and obligations of the respective parties under the License, all to the substantial benefit of Bakhu.

E.                  VOLC is a privately held California corporation with principal offices in California that is positioned to undertake the Efficacy Demonstration, at the direction of OZ, which involves handling cannabis and cannabis components, products, or derivatives.

F.                  OZ owns a majority of the voting control of Bakhu and is a principal stockholder of Cell Science. As such, OZ will directly and indirectly realize substantial financial benefits on successful completion of the Efficacy Demonstration and wanted to realize the benefits of being directly involved in the testing in order to minimize reliance on third parties. Therefore, OZ was willing to manage and advance funds initially to undertake the Efficacy Demonstration and had cash and access to cash and other liquid resources to enable it to immediately commence work leading toward the Efficacy Demonstration.

G.                 Bakhu is a Nevada corporation with a class of equity securities registered under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) and, as such, wants to avoid handling cannabis and cannabis components, products, or derivatives. Nevertheless, Bakhu realizes the benefits resulting from successful completion of the Efficacy Demonstration in order to implement Bakhu’s business goal of sublicensing to third parties the technology with which they can produce cannabis and cannabis components, products, or derivatives.

H.                 Bakhu has substantially strengthened its management and financial resources and is now better positioned to assume financial and management responsibility for the Efficacy Demonstration, commencing as of the Effective Date. Under the foregoing circumstances, Bakhu desires to engage OZ to continue to be directly responsible for completing the Efficacy Demonstration required by the R&D Agreement on the terms and conditions set forth below.

I.                    Each of the parties and entities identified above has received, and had the opportunity to review, all of the agreements identified above.

Agreement

NOW, THEREFORE, upon these premises, which are incorporated herein by this reference, and for and in consideration of the mutual promises and covenants set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

1.                   Laboratory Testing. From and after the Effective Date, OZ will continue, with diligence and dispatch, commercially reasonable steps to establish the necessary laboratory Facility and related support to prepare for and complete the Efficacy Demonstration as required under the R&D Agreement, including the purchase and installation of equipment, the engagement of consultants, the purchase of supplies and materials, the establishment of operating protocols and procedures, and the acquisition of all permits and authorizations, and in cooperation with VOLC, the engagement of employees for VOLC for the R&D Agreement activities, the satisfaction of all regulatory, safety, reporting, and similar requirements, and all other steps necessary to complete an Efficacy Demonstration as required by the License.

2.                   Collaboration and Laboratory Access. OZ will, at all times until completion of the Efficacy Demonstration, collaborate and cooperate with Bakhu to assure its full participation in and familiarity with OZ’s day-by-day efforts under this Agreement, including providing qualified representatives of Bakhu, at its own expense, access to the test Facility during OZ’s actual hours of operation, provided that a duly authorized representative of OZ is present. Bakhu’s representatives will comply with all of OZ’s safety and operating protocols and requirements and bear all risks of its personnel in the Facility.

3.                   Cost Advances; Accounting; Auditing. OZ will be solely responsible for paying and otherwise discharging all financial and other obligations for work toward the Efficacy Demonstration prior to the Effective Date. Commencing on the Effective Date, OZ will advance, on Bakhu’s behalf, all costs and expenses necessary and appropriate to fulfill its obligations hereunder to complete the Efficacy Demonstration. Periodically, but in any event within 20 days after the end of each calendar quarter until work under this Agreement is terminated, OZ will provide Bakhu with an accounting setting forth in reasonable detail the costs and expenses incurred by OZ under this Agreement, accompanied by supporting purchase orders, invoices, and similar original entry records, which will be in sufficient detail to meet standards applicable to Bakhu’s preparation of audited financial statements. At Bakhu’s reasonable request, OZ will supplement this accounting and supporting documents. From time to time, on not less than 20 days’ prior notice to OZ, Bakhu will have the right during OZ’s regular business hours, to review and examine OZ’s books and records respecting the accounting maintained under this Agreement and to seek adjustment of such accounting to assure the accrual of costs and expenses in accordance with this Agreement.

4.                   Repayment of OZ Costs of Testing. Bakhu will repay all costs incurred by OZ after the Effective Date in performing the Efficacy Demonstration in accordance with this Agreement on 180 days’ demand, which may be given at any time after successful completion or abandonment of the effort to complete the Efficacy Demonstration. Until paid, these costs will bear simple interest at 6% per year commencing on the last day of the month in which such costs were incurred and properly billed as provided herein. Payment will be in cash, unless OZ elects to accept shares of common stock of Bakhu valued at a price equivalent to 80% of the 30 trading-day trailing volume weighted average trading closing price for Bakhu stock on the principal trading market for its shares.

5.                   Reports. Within 20 days after the end of each calendar quarter and on attaining any significant individual or group of related test results, OZ will deliver a written report in reasonable technical and commercial detail summarizing laboratory results during the period or upon such event. These reports will be accurate and complete in all material respects. Such reports will be treated as confidential for purposes of this Agreement but will serve as the basis for public disclosures by Bakhu in accordance with its responsibilities under the Exchange Act and any securities exchange on which its securities may be listed.

6.                   Works for Hire. All work based on, derived from, or related to the licensed technology and intellectual property and all modifications, improvements, derivations, or extensions thereof that are created by OZ or VOLC, in any form and expression, will be and are considered “works for hire.” As such, Bakhu will be considered the exclusive owner of all proprietary rights, including federal copyrights, in and to all modifications, improvements, derivations, or extensions of the intellectual property covered by the License. For purposes hereof, the term “work for hire” has the meaning defined in the United States Copyright Act, Section 101 of Title 17 of the United States Code. Bakhu will have exclusive rights in and to all modifications, improvements, derivations, or extensions of the intellectual property that are available to the author or owner of a United States copyright and any other intellectual property rights. To the extent that any modifications, improvements, derivations, or extensions of the intellectual property that are created by OZ or VOLC are not considered as works for hire, each of OZ and VOLC hereby assigns, transfers, and sets over unto Bakhu all rights, title, and interest in and to all such modifications, improvements, derivations, or extensions.

7.                   Confidentiality.

(a)                The data and information, particularly including results of laboratory work relating to the Efficacy Demonstration and the costs and expenses incurred in connection therewith, will be deemed “Confidential Material” under this Agreement.

(b)                OZ will keep the Confidential Material strictly confidential and will not use the Confidential Material for any purpose other than to fully and faithfully perform its obligations under this Agreement. OZ will not disclose, or permit agents or agent or representatives to disclose, any Confidential Material, except: (i) if required by law, regulation, and legal and regulatory process, but only in accordance with this section; and (ii) to its agents or representatives to the extent necessary to permit such persons to assist OZ in discharging its obligations hereunder; provided, that OZ will require each such agent or representative to be bound by the terms of this Agreement to the same extent as if he or she were a party hereto. OZ will be responsible for any breach of this Agreement by any of its agents or representatives, it being understood that this responsibility will be in addition to and not by way of limitation of any right and remedy Bakhu may have against the agent or agent or representative for any breach).

(c)                Notwithstanding subsection (b) above, if OZ is required by law, regulation, and legal and regulatory process or requested by a regulatory or self-regulatory authority (collectively, “Law”) to disclose all or any portion of the Confidential Material, OZ will, to the extent permitted by Law, promptly notify Bakhu of such requirement or request so that Bakhu may seek (at its sole expense) a protective order or other appropriate remedy. If, in the absence of a protective order or other appropriate remedy or the receipt of a waiver hereunder, OZ is nonetheless, based on the advice of its counsel, compelled by Law to disclose all or part of the Confidential Material, then OZ may disclose (without any liability hereunder) only that portion of the Confidential Material that, based on the advice of its counsel, OZ is required to disclose. Notwithstanding anything herein to the contrary, OZ may disclose (without any liability hereunder) Confidential Material in connection with any routine inspection, investigation, examination, or inquiry (not specifically targeting Bakhu) by a regulatory or self-regulatory authority having jurisdiction over OZ without providing notice to Bakhu or taking any other action hereunder.

(d)                All Confidential Material is and remains the property of Bakhu, and no right or license is granted to the OZ respecting any Confidential Material. Within 60 days after the expiration of this Agreement, OZ will promptly, and in any event no later than five days after the request, deliver all Confidential Material (including all copies, extracts, and other reproductions) to Bakhu or destroy such Confidential Material (including any Confidential Material held electronically) and certify in writing to Bakhu that all Confidential Material (including any Confidential Material held electronically) has been destroyed. Notwithstanding the return or destruction of Confidential Material, OZ will continue to be bound by its confidentiality and other obligations hereunder.

(e)                The parties agree that monetary damages would not be a sufficient remedy for any breach of this Agreement by OZ and that in addition to all other remedies, Bakhu may be entitled to seek specific performance and injunctive or other equitable relief as a remedy for any such breach.

8.                   Insurance. For so long as this Agreement (or any subsequent agreement that provides for the use of the Facility) is in place, OZ will obtain and maintain at its own cost and expense, from a qualified insurance company, real and personal property insurance, with a minimum coverage at least equivalent to that set forth on the Certificate of Insurance attached hereto as Appendix A and incorporated herein by reference. Within 10 days after the execution of this Agreement, OZ will instruct the insurer to name “Bakhu Holdings, Corp. and its subsidiaries and affiliates” as additional insureds and to identify the coverage as primary over any and all other applicable coverages. The insurance policy must provide for 30 days’ prior written notice to Bakhu from the insurer, by registered or certified mail, return receipt requested, in the event of any modification, cancellation, or termination. Upon renewal or Bakhu’s request, OZ will provide to Bakhu insurance certificates to evidence continuous required coverage.

9.                   Term. The term of this Agreement will continue for a period of 180 days after the completion of the Efficacy Demonstration.

10.               Governing Law; Venue. This Agreement is being executed and delivered, and is intended to be performed, in the state of California, and to the extent permitted by law, the execution, validity, construction, and performance of this Agreement will be construed and enforced in accordance with the laws of the state of California without giving effect to conflict of law principles. This Agreement will be deemed made and entered into in Los Angeles County, State of California, and venue for any Proceeding (as defined below), in connection with this Agreement will be in Los Angeles County, California.

11.               Waiver of Jury Trial. The parties hereto hereby voluntarily and irrevocably waive trial by jury in any Proceeding brought in connection with this Agreement, any of the related agreements and documents, and any of the transactions contemplated hereby or thereby. For purposes of this Agreement, “Proceeding” includes any threatened, pending, or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing, and any other actual, threatened, or completed proceeding, whether brought by or in the right of any party to this Agreement or otherwise and whether civil, criminal, administrative, or investigative, in which a party to this Agreement was, is, or will be involved as a party or otherwise.

12.               Merger; Integration. This Agreement sets forth the entire agreement regarding the matters set forth herein and supersedes all prior negotiations, understandings, and agreements. No provision of this Agreement may be modified, waived, and changed except by a writing signed by the parties hereto.

13.               Notices. Any notice, demand, request, or other communication permitted or required under this Agreement will be in writing and will be deemed to have been given as of the date so delivered, if personally delivered; as of the date so sent, if sent by electronic mail and receipt is acknowledged by the recipient; one day after the date so sent, if delivered by overnight courier service; or three days after the date so mailed, if mailed by certified mail, return receipt requested, addressed as follows:

If to OZ, to:

The Oz Corporation

Attn: JR Munoz, President

One World Trade Center, Suite 130

Long Beach, CA 90831

E-mail: tkemmitt@yahoo.com

If to Bakhu to:

Bakhu Holdings, Corp.

Attn: Thomas E. Emmitt, President

One World Trade Center, Suite 130

Long Beach, CA 90831

E-mail: jrmun@msn.com

Notwithstanding the foregoing, service of legal process or other similar communications will not be given by electronic mail and will not be deemed duly given under this Agreement if delivered by such means. Each party, by notice duly given in accordance herewith, may specify a different address for the giving of any notice hereunder.

14.               No Assignment. Neither this Agreement nor any of the rights and obligations hereunder may be assigned by any party without the prior written consent of the nonassigning party. Any purported assignment without such consent will be void and unenforceable.

15.               Counterpart Execution. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which together will constitute a single agreement. Counterpart signatures of this Agreement that are manually signed and delivered by facsimile transmission, by a uniquely marked computer-generated signature, and by other electronic methods, will be deemed to constitute signed original counterparts hereof and will bind the parties signing and delivering in such manner and will be the same as the delivery of an original.

*** Signature Page Follows ***

IN WITNESS WHEREOF, the parties have executed this Agreement to be effective as of the date first above written.